An NHS hospital trust has formally rejected claims that deliberate changes to life-sustaining dialysis treatments were responsible for a higher-than-expected number of deaths among renal patients, while conceding that the care delivered during the period fell below accepted clinical standards.

The trust acknowledged that dialysis sessions were modified during a period it described as one of "exceptional" capacity pressure, but maintained that an internal investigation found no evidence of a causal link between those modifications and the mortality figures that subsequently prompted scrutiny. The dual admission, that standards slipped and yet patients were not harmed by that failure, has drawn immediate challenge from patient groups and independent clinicians, who argue that the conclusion requires verification beyond the trust's own review.

The modifications were introduced during a period in which the renal unit faced acute pressure across multiple fronts. Staff shortages left wards operating below safe staffing ratios, while a sustained increase in patient referrals placed further strain on already stretched dialysis capacity. Equipment availability compounded the problem, with a reduced number of functioning machines limiting the number of concurrent treatments that could be administered.

Clinicians and unit managers faced a choice between reducing the number of patients receiving treatment or altering the parameters of individual sessions to accommodate a larger patient volume. The decision to alter sessions was not, according to documents reviewed by this newspaper, formalised through an emergency protocol agreed in advance. Frontline staff implemented changes under operational duress, with modifications varying between patients and across different shifts.

Standard haemodialysis requires sessions of approximately four hours, conducted three times per week. That schedule reflects the rate at which accumulated toxins, primarily urea and creatinine, must be cleared from the bloodstream to prevent deterioration in patients whose kidneys have failed entirely. Compression of session length, or reduction in weekly frequency, directly affects the volume of waste cleared. The trust confirmed that some patients received sessions shorter than the four-hour standard and that in a number of cases the frequency of treatment was reduced. Monitoring during sessions was also reported to have been less consistent than protocols require.

Under-dialysis carries documented risks. Patients accumulate excess fluid and toxins between sessions, increasing strain on the cardiovascular system and raising the risk of hyperkalaemia, a dangerous elevation in potassium levels that can cause cardiac arrest. For patients with existing heart disease or diabetes, both common in the renal population, those risks are amplified.

The higher-than-expected death rate among renal patients over the relevant period was identified through routine mortality surveillance. The precise number of deaths under review has not been publicly disclosed by the trust, though sources familiar with the investigation indicated it exceeded statistical projections by a margin significant enough to trigger a formal inquiry. The trust's internal review concluded that the deaths were attributable primarily to underlying patient comorbidities, including advanced cardiovascular disease and diabetes, and to broader mortality pressures consistent with winter demand and, where applicable, the residual effects of the pandemic period.

The Renal Association and several patient advocacy organisations have called for an independent audit of both the clinical data and the methodology of the trust's internal review. Their concern is not simply whether the conclusion is correct, but whether an institution investigating its own conduct under legal and reputational pressure is positioned to reach a reliable one.

NHS England has been notified, and the Care Quality Commission is understood to be assessing whether a formal regulatory inspection is warranted. The trust has stated it will cooperate fully with any external review. What the process has yet to produce is an account that does not originate from the trust itself. Until independent clinicians examine the patient records and the mortality data, the gap between the operational admission and the clinical conclusion will remain contested.

‍